The U.S. Food and Drug Administration (FDA) has approved two new indications for the osteoporosis drug denosumab, as a treatment for bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer and in women receiving adjuvant aromatase inhibitor therapy for breast cancer.
Wide variations in the care of early bladder cancer exist, and among high–treatment intensity urology providers, overall survival is unchanged while rates of transition to major surgery are actually increasing. It has been said that for bladder tumors, it is time for a paradigm shift. We believe that the time is overdue.
Bladder cancer is a complex neoplasm with multiple histologic subtypes and a wide spectrum of clinical states, ranging from relatively nonlethal Ta cancers to virulent M1 disease.
In this issue of ONCOLOGY, Kamat and Mathew provide an excellent overview of the current status and future imperatives of bladder cancer treatment and research.
Cabozantinib (cabo), formerly known as XL184, has recently shown unprecedented activity against bone metastases in prostate cancer patients in a phase II trial.
The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass. He underwent a radical nephrectomy for a 19-cm large-cell, poorly differentiated neoplasm, consistent with pleomorphic, epithelioid angiomyolipoma (EAML) with extensive necrosis and cytologic atypia.
Researchers have found that patients with early, localized prostate cancer benefit from short-term androgen-deprivation therapy (ADT) for 4 months prior to and during radiotherapy, and that the addition of ADT increases overall survival and decreases mortality.
Scientists at the Center for Translational Pathology and the department of urology at the University of Michigan Medical School have developed a new noninvasive urine test for prostate cancer that may be able to stratify patients by risk.
Hoppe et al present an excellent review of the physics relevant to an understanding of proton therapy-and of the available literature assessing the use of proton beams in the management of prostate cancer.
This review discusses the rationale, history, and current status of proton therapy for prostate cancer-and controversies regarding it.
At the session on Management of Prostate Cancer in Older Adults: To Treat or not to Treat, Anthony D’Amico, William Dale, and Shabbir Alibhai all lent their clinical expertise in treating prostate cancer to outline the latest recommendations for screening and treating men for prostate cancer.
Abiraterone acetate has been shown to significantly acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer (CRPC) who previously received chemotherapy. The results of the Phase III study were published in the May 26, 2011 edition of the New England Journal of Medicine.
A retrospective study of metastatic renal cell carcinoma (mRCC) patients published in the journal Cancer found that patients treated with tyrosine kinase inhibitors (TKIs) had better overall survival and less-frequent metastasis to the brain.
Drs. Ruch and Hussain provide an excellent overview of the emerging therapeutic agents and targets for advanced prostate cancer.
The article by Ruch and Hussain provides a comprehensive overview of the progress that has been made in translating basic science findings in prostate cancer biology to clinical trials.
This article will present a detailed review of the body of evidence regarding the PSA assay, with reflections on the resulting future of prostate cancer screening.
This review will discuss recently FDA-approved agents for advanced prostate cancer and those under investigation in phase III trials.
Prostate cancer screening using prostate-specific antigen (PSA) testing has been a contentious subject.
The controversy surrounding PSA screening is one of the most heated in oncology. The potential benefits include prevention of prostate cancer morbidity and mortality, but the men potentially harmed through overdiagnosis and overtreatment outnumber those who benefit.
A large-scale, retrospective study published in the JNCI has now shown that men who take statins had lower incidence of total and high-grade prostate cancer compared with men who took antihypertensive medications.
Following a retrospective analysis which may be the largest of its kind to date, a multicenter team of investigators says treatment-related hypertension may be a useful biomarker of superior clinical outcome with sunitinib (Sutent) in patients with metastatic renal cell carcinoma (RCC).
On April 28, the FDA announced the approval of abiraterone acetate (Zytiga) in conjunction with a steroid, prednisone, as treatment for late-stage (metastatic) castration-resistant prostate cancer patients who have received prior docetaxel.
My 2002 article provided an overview of the various interleukin-2 (IL-2)–based treatment regimens that had been explored over the preceding two decades
An analysis of data from 3,400 men in the large nationwide Prostate Cancer Prevention Trial indicates that, contrary to what might be expected, men with the highest blood percentages of DHA (docosahexaenoic acid), an omega-3 fatty acid commonly found in fatty fish, had 2.5 times the risk of developing aggressive, high-grade prostate cancer, compared with men who had the lowest levels.
The question of whether men with low-risk prostate cancer should have their cancers vigilantly monitored is an ongoing issue for the National Comprehensive Cancer Network (NCCN) Panel on prostate cancer.
